Northern Trust’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-448,257
| Closed | -$43.5M | – | 4330 |
|
|
2019
Q3 | $43.5M | Buy |
448,257
+39,295
| +10% | +$3.93M | 0.01% | 1077 |
|
|
2019
Q2 | $41.9M | Buy |
408,962
+4,004
| +1% | +$432K | 0.01% | 1137 |
|
|
2019
Q1 | $46.1M | Buy |
404,958
+8,946
| +2% | +$658K | 0.01% | 1023 |
|
|
2018
Q4 | $15.5M | Buy |
396,012
+5,381
| +1% | +$233K | ﹤0.01% | 1781 |
|
|
2018
Q3 | $21.3M | Buy |
390,631
+9,812
| +3% | +$671K | 0.01% | 1745 |
|
|
2018
Q2 | $31.5M | Buy |
380,819
+41,723
| +12% | +$3.22M | 0.01% | 1396 |
|
|
2018
Q1 | $22.6M | Buy |
339,096
+3,743
| +1% | +$216K | 0.01% | 1594 |
|
|
2017
Q4 | $17.2M | Buy |
335,353
+2,089
| +0.6% | +$150K | ﹤0.01% | 1829 |
|
|
2017
Q3 | $29.7M | Buy |
333,264
+45,806
| +16% | +$3.48M | 0.01% | 1394 |
|
|
2017
Q2 | $17.2M | Buy |
287,458
+43,199
| +18% | +$2.41M | ﹤0.01% | 1795 |
|
|
2017
Q1 | $13M | Buy |
244,259
+15,050
| +7% | +$894K | ﹤0.01% | 1920 |
|
|
2016
Q4 | $11.4M | Buy |
229,209
+2,929
| +1% | +$157K | ﹤0.01% | 2022 |
|
|
2016
Q3 | $13.6M | Buy |
226,280
+24,322
| +12% | +$1.4M | ﹤0.01% | 1858 |
|
|
2016
Q2 | $10.3M | Buy |
201,958
+92,397
| +84% | +$3.95M | ﹤0.01% | 2003 |
|
|
2016
Q1 | $3.23M | Buy |
109,561
+12,626
| +13% | +$398K | ﹤0.01% | 2695 |
|
|
2015
Q4 | $4.39M | Buy |
96,935
+4,959
| +5% | +$260K | ﹤0.01% | 2535 |
|
|
2015
Q3 | $3.84M | Buy |
91,976
+9,392
| +11% | +$490K | ﹤0.01% | 2610 |
|
|
2015
Q2 | $4.98M | Buy |
82,584
+62,297
| +307% | +$4.12M | ﹤0.01% | 2521 |
|
|
2015
Q1 | $1.57M | Buy |
+20,287
| New | +$1.17M | ﹤0.01% | 3246 |
|
Northern Trust's ONCE Position: Q4 2019 in Review
Northern Trust sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 448,257 shares — an estimated $43.5M sold.
Northern Trust first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $46.1M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Northern Trust reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Northern Trust sold 448,257 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $43.5M.
- Northern Trust first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Northern Trust's Spark Therapeutics, Inc. Common Stock position peaked at $46.1M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Northern Trust's 13F filing for Q4 2019, filed 14 Feb 2020.